知情人士透露，KKR & Co.支持的风险投资公司Catalio Capital Management正寻求筹集5亿美元，支持AI医疗初创企业，这是该公司16个月内的第二次募资。
KKR & Co.-backed venture capital firm Catalio Capital Management is seeking to raise $500 million to back AI healthcare startups, its second fundraise in 16 months, according to people familiar with the matter.
Catalio在一封投资者信中表示，人工智能技术正在加速医疗创新，催生出将AI与生物医学和临床护理相结合的“定义类别”的企业。彭博新闻社查阅了这封信。
Artificial intelligence technologies are speeding up healthcare innovation, creating “category-defining” businesses that are combining AI with biomedicine and clinical care, Catalio said in a letter to investors viewed by Bloomberg News.
该公司在信中表示，Catalio将其Nexus V基金的启动时间从2027年提前，以“抓住这一千载难逢的机遇”。
Catalio accelerated the launch of its Nexus V fund from 2027 to “capitalize on this once-in-a-generation opportunity,” the firm said in the letter.
知情人士透露，该公司最近一只基金于2025年7月完成募资，规模超过4亿美元。其中，涉及AI的公司投资占该组合的40%，Catalio预计新基金的组成将类似。这些人士因讨论私人信息而要求匿名。
Its most recent fund closed in July 2025 with more than $400 million. Investments in companies with AI exposure comprised 40% of that portfolio, and Catalio expects a similar composition for the new fund, according to the people, who asked not to be named discussing private information.
五项现有投资将转入新基金，包括自称“你的私人AI医生”的Doctronic，以及开发AI设计“疗法”的Basecamp Research。Catalio的一位代表拒绝就募资及其他细节发表评论。
Five existing investments will be rolled into the new fund, including Doctronic, which calls itself “your personal AI doctor,” and Basecamp Research, which develops AI-designed “therapeutics.”A representative for Catalio declined to comment on the fundraise and other details.
据英伟达公司的一项调查，约70%的医疗和生命科学公司正在积极使用AI，较去年的63%有所上升，其中制药和生物技术公司是最热衷的采用者之一。
Roughly 70% of healthcare and life sciences firms are actively using AI, up from 63% last year, according to a survey by Nvidia Corp, with pharmaceutical and biotech companies among the most enthusiastic adopters.
今年以来，Catalio已出售三家投资组合公司，交易总额超过80亿美元。该公司还使七家公司上市，包括本周Iambic Therapeutics的1.5亿美元首次公开募股，以及Parabilis Medicines Inc在6月完成的7.45亿美元首次公开募股。该公司在信中表示，还预计Enveda Biosciences和Imperative Care也将上市。
So far this year, Catalio has sold three portfolio companies in transactions worth more than $8 billion in total. It’s also taken seven companies public, including this week’s $150 million IPO of Iambic Therapeutics and the $745 million debut of Parabilis Medicines Inc in June. It expects Enveda Biosciences and Imperative Care to go public as well, the firm said in the letter.
KKR于2023年收购了Catalio的少数股权，私募股权公司的联合创始人亨利·克拉维斯担任董事会主席。董事会还包括Thoma Bravo联合创始人奥兰多·布拉沃以及HPS投资合伙公司的创始合伙人兼联合总裁迈克尔·帕特森，该公司目前是BlackRock Inc.的子公司。
KKR took a minority stake in Catalio in 2023, and the private equity firm’s, co-founder Henry Kravis, serves as board chair. The board also includes Thoma Bravo co-founder Orlando Bravo and Michael Patterson, founding partner and co-president of HPS Investment Partners, now a BlackRock Inc. company.